Skip to main content
OpenTrials
Completed

NCT Number: NCT06612333

Evaluation of the French Version of the PEERS Social Skills Training Program for Adolescents With Rare Neurodevelopmental Disorders

Adolescents and young adults with rare neurodevelopmental disorders are at risk of developing psychiatric pathologies during the transition to adulthood. Loneliness and lack of social relationships can lead to anxiety and depression in adolescents and young adults with rare neurodevelopmental disorders. Anxiety and depression are major risk factors for the transition to psychiatric symptoms in adulthood. The improvement of social skills and the positive evolution of social relationships in adolescents and young adults with rare neurodevelopmental disorders can lead to a reduction in the risk factors for anxiety and depression. It therefore seems essential to evaluate the evolution of social skills in this population of young adults under the care of the social skills program, PEERS, in France to assess the overall benefit of the program, particularly in this population of young people with rare neurodevelopmental disorders.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Neurodevelopmental Disorders Disease Attributes Mental Disorders Pathologic Processes Pathological Conditions, Signs and Symptoms Rare Diseases

Age range

12 year–30 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Necker - Enfants Malades Hospital

Paris, Île-de-France Region, 75015, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged between 12 and 30 years, included at the start of the social skills program.
  • Patients with rare neurodevelopmental diseases
  • Patients benefiting from the social skills program
  • Appropriate level of verbal elaboration
  • Patient with a family member or a friend also participating in the social skills program

Non-inclusion criteria :

  • Opposition of the patient or, if a minor, of his/her parents to participation in the study
  • Patient not psychiatrically stabilized: acute symptoms of anxiety, depression, psychotic disorders.
  • Severe intellectual disability

Treatment and study plan

Primary outcomes

  1. Assessment of social skills in adolescents and young adults with rare neurodevelopmental diseases participating in the social skills program

    Time frame: 2023 - 2025

    Quality of Play Questionnaire-Adolescent (QPQ-A) (QSQP in French)

  2. Assessment of social skills in adolescents and young adults with rare neurodevelopmental diseases

    Time frame: 2023 - 2025

    Friendship Quality Scale (FQS)

  3. Assessment of social skills in adolescents and young adults with rare neurodevelopmental diseases

    Time frame: 2023 - 2025

    Social Anxiety Scale for Adolescent (SAS-A)

  4. Assessment of social skills in adolescents and young adults with rare neurodevelopmental diseases

    Time frame: 2023 - 2025

    Loneliness and Social Dissatisfaction Scale (L&SD)

  5. Assessment of social skills in adolescents and young adults with rare neurodevelopmental diseases

    Time frame: 2023 - 2025

    Test of Adolescent Social Skills Knowledge (TASSK)

  6. Assessment of social skills in adolescents and young adults with rare neurodevelopmental diseases

    Time frame: 2023 - 2025

    Self-Assessment of Conversational Skills (AHC)

  7. Assessment of social skills in adolescents and young adults with rare neurodevelopmental diseases

    Time frame: 2023 - 2025

    Beck Youth Inventories (BYI)

Sponsors and collaborators

Lead sponsor

Imagine Institute

Other

Registry information

Official study title

Evaluation of the French Version of the PEERS Social Skills Training Program for Adolescents With Rare Neurodevelopmental Disorders / PEERS-MRND

Acronym: PEERS-MRND

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Sep 25, 2024
Registry last updated
Nov 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.